Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer

被引:36
|
作者
Eide, Peter W. [1 ,2 ]
Moosavi, Seyed H. [1 ,2 ,3 ]
Eilertsen, Ina A. [1 ,2 ,3 ]
Brunsell, Tuva H. [1 ,2 ,3 ,4 ]
Langerud, Jonas [1 ,2 ,3 ]
Berg, Kaja C. G. [1 ,2 ,3 ]
Rosok, Bard I. [2 ,4 ]
Bjornbeth, Bjorn A. [2 ,4 ]
Nesbakken, Arild [2 ,3 ,4 ]
Lothe, Ragnhild A. [1 ,2 ,3 ]
Sveen, Anita [1 ,2 ,3 ]
机构
[1] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway
[2] Oslo Univ Hosp, Div Canc Med, KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Oslo Univ Hosp, Dept Gastrointestinal Surg, Oslo, Norway
关键词
BRAF MUTATION; IMPACT; BIOMARKERS; PROGNOSIS; EVOLUTION;
D O I
10.1038/s41525-021-00223-7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gene expression-based subtypes of colorectal cancer have clinical relevance, but the representativeness of primary tumors and the consensus molecular subtypes (CMS) for metastatic cancers is not well known. We investigated the metastatic heterogeneity of CMS. The best approach to subtype translation was delineated by comparisons of transcriptomic profiles from 317 primary tumors and 295 liver metastases, including multi-metastatic samples from 45 patients and 14 primary-metastasis sets. Associations were validated in an external data set (n = 618). Projection of metastases onto principal components of primary tumors showed that metastases were depleted of CMS1-immune/CMS3-metabolic signals, enriched for CMS4-mesenchymal/stromal signals, and heavily influenced by the microenvironment. The tailored CMS classifier (available in an updated version of the R package CMScaller) therefore implemented an approach to regress out the liver tissue background. The majority of classified metastases were either CMS2 or CMS4. Nonetheless, subtype switching and inter-metastatic CMS heterogeneity were frequent and increased with sampling intensity. Poor-prognostic value of CMS1/3 metastases was consistent in the context of intra-patient tumor heterogeneity.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] DISTINCT PATIENT AND TUMOR CHARACTERISTICS OF THE CONSENSUS MOLECULAR SUBTYPES OF COLORECTAL CANCER
    Davis, Jennifer S.
    Yu, Ruoxi
    Banerjee, Madhulika
    Jiang, Zhi-Qin
    Menter, David G.
    Guinney, Justin
    Morris, Jeffrey
    Broom, Bradley M.
    Maru, Dipen
    Manyam, Ganiraju C.
    Chang, Shine
    Kopetz, Scott
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S880 - S880
  • [32] Consensus molecular subtypes in colorectal cancer differ by geographic region.
    Korphaisarn, Krittiya
    Lam, Michael
    Loree, Jonathan M.
    Ruiz, Erika
    Aguiar, Samuel
    Kopetz, Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
    Valenzuela, Guillermo
    Canepa, Joaquin
    Simonetti, Carolina
    Solo de Zaldivar, Loreto
    Marcelain, Katherine
    Gonzalez-Montero, Jaime
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1000 - 1008
  • [34] Histopathology of Colorectal Cancer in the Context of Consensus Molecular Subtypes and Prognostic Implication
    Luo, Wenyi
    Katkhuda, Riham
    Kopetz, Scott
    Menter, David
    Morris, Jeffrey
    Maru, Dipen
    [J]. LABORATORY INVESTIGATION, 2019, 99
  • [35] Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models
    Linnekamp, Janneke F.
    van Hooff, Sander R.
    Prasetyanti, Pramudita R.
    Kandimalla, Raju
    Buikhuisen, Joyce Y.
    Fessler, Evelyn
    Ramesh, Prashanthi
    Lee, Kelly A. S. T.
    Bochove, Grehor G. W.
    de Jong, Johan H.
    Cameron, Kate
    van Leersum, Ronald
    Rodermond, Hans M.
    Franitza, Marek
    Nuernberg, Peter
    Mangiapane, Laura R.
    Wang, Xin
    Clevers, Hans
    Vermeulen, Louis
    Stassi, Giorgio
    Medema, Jan Paul
    [J]. CELL DEATH AND DIFFERENTIATION, 2018, 25 (03): : 616 - 633
  • [36] Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models
    Janneke F. Linnekamp
    Sander R. van Hooff
    Pramudita R. Prasetyanti
    Raju Kandimalla
    Joyce Y. Buikhuisen
    Evelyn Fessler
    Prashanthi Ramesh
    Kelly A. S. T. Lee
    Grehor G. W. Bochove
    Johan H. de Jong
    Kate Cameron
    Ronald van Leersum
    Hans M. Rodermond
    Marek Franitza
    Peter Nürnberg
    Laura R. Mangiapane
    Xin Wang
    Hans Clevers
    Louis Vermeulen
    Giorgio Stassi
    Jan Paul Medema
    [J]. Cell Death & Differentiation, 2018, 25 : 616 - 633
  • [37] Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
    Linnekamp, Janneke F.
    Wang, Xin
    Medema, Jan Paul
    Vermeulen, Louis
    [J]. CANCER RESEARCH, 2015, 75 (02) : 245 - 249
  • [38] Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)
    Stahler, Arndt
    Heinemann, Volker
    Schuster, Veronika
    Heinrich, Kathrin
    Kurreck, Annika
    Giessen-Jung, Clemens
    von Weikersthal, Ludwig Fischer
    Kaiser, Florian
    Decker, Thomas
    Held, Swantje
    Graeven, Ullrich
    Schwaner, Ingo
    Denzlinger, Claudio
    Schenk, Michael
    Neumann, Jens
    Kirchner, Thomas
    Jung, Andreas
    Kumbrink, Jorg
    Stintzing, Sebastian
    Modest, Dominik P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 157 : 71 - 80
  • [39] Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
    Chowdhury, Saikat
    Hofree, Matan
    Lin, Kangyu
    Maru, Dipen
    Kopetz, Scott
    Shen, John Paul
    [J]. CANCERS, 2021, 13 (19)
  • [40] Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
    Wlodarczyk, Marcin
    Wlodarczyk, Jakub
    Siwinski, Pawel
    Sobolewska-Wlodarczyk, Aleksandra
    Fichna, Jakub
    [J]. CURRENT DRUG TARGETS, 2018, 19 (15) : 1731 - 1737